UK markets close in 2 hours 22 minutes
  • FTSE 100

    5,594.18
    -134.81 (-2.35%)
     
  • FTSE 250

    17,279.25
    -308.46 (-1.75%)
     
  • AIM

    954.24
    -18.29 (-1.88%)
     
  • GBP/EUR

    1.1060
    -0.0000 (-0.00%)
     
  • GBP/USD

    1.2981
    -0.0060 (-0.46%)
     
  • BTC-GBP

    10,070.75
    -450.21 (-4.28%)
     
  • CMC Crypto 200

    259.18
    -13.50 (-4.95%)
     
  • S&P 500

    3,316.99
    -73.69 (-2.17%)
     
  • DOW

    26,872.77
    -590.42 (-2.15%)
     
  • CRUDE OIL

    37.34
    -2.23 (-5.64%)
     
  • GOLD FUTURES

    1,876.50
    -35.40 (-1.85%)
     
  • NIKKEI 225

    23,418.51
    -67.29 (-0.29%)
     
  • HANG SENG

    24,708.80
    -78.39 (-0.32%)
     
  • DAX

    11,607.73
    -455.84 (-3.78%)
     
  • CAC 40

    4,574.49
    -156.17 (-3.30%)
     

Edison Investment Research Limited: RhoVac (RHOVAC): Good execution in challenging times for industry

·2-min read

Edison Investment Research Limited
05-Oct-2020 / 10:39 GMT/BST

 

London, UK, 5 October 2020

RhoVac (RHOVAC): Good execution in challenging times for industry

On the back of a crystal-clear R&D strategy, to conduct a proof-of-concept study and then seek a partnership deal, RhoVac completed a successful fundraise in June 2019 and started enrolling patients in the Phase IIb BRaVac study in November 2019. Due to the COVID-19 pandemic full enrolment is now expected by end-2020 vs the original target of Q320. In our view the delay is modest and easily covered by the existing budget. Clinical trial centres are up and running, including in the US, and treatment results are still expected by the end of 2021. So overall, this shows good execution in what has been a challenging period for the whole industry. Our updated valuation is SEK1.18bn or SEK61.8/share.

 

Our RhoVac valuation is higher at SEK1.18bn or SEK61.8/share due to revised rNPV assumptions, rolling the model forward and a lower cash position (SEK109.7m at end-Q220). As RhoVac is making progress with the Phase IIb trial and more details about RV001's potential are available, our review is primarily focused on the licensing potential, which is presented in the valuation section.


Click here to view the full report.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Jonas Peciulis, +44 (0)20 3077 5728

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        https://www.linkedin.com/company/edison-group-

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement - EQS News Service

show this
show this